Showing 1 - 4 results of 4 for search 'Joyce S Plested', query time: 0.02s Refine Results
  1. 1
    A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

    A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation by Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Benjamin Haner, Mi Wang, Bahar Osman, Dominic Dent, Sheau-Line Feng, Zach Longacre, Greg Glenn, Joyce S. Plested

    Published 2024-02-01
    Get full text
    Article
  2. 2
    Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity

    Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity by Zhaohui Cai, Raj Kalkeri, Mi Wang, Benjamin Haner, Dominic Dent, Bahar Osman, Paul Skonieczny, Jeremy Ross, Sheau-Line Feng, Rongman Cai, Mingzhu Zhu, Shane Cloney-Clark, Joyce S. Plested

    Published 2024-06-01
    Get full text
    Article
  3. 3
    A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine

    A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombina... by Timothy S. Vincent, Mingzhu Zhu, Anand Parekh, Urvashi Patel, Shane Cloney-Clark, Andrew Klindworth, David Silva, Andrew Gorinson, Karlee Miranda, Mi Wang, Zachary Longacre, Bin Zhou, Iksung Cho, Rongman Cai, Raj Kalkeri, Louis Fries, Vivek Shinde, Joyce S. Plested

    Published 2024-11-01
    Get full text
    Article
  4. 4
    Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

    Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in pe... by Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi S. L. Masilela, Dhayendre Moodley, Sherika Hanley, Leon Frederik Fouche, Cheryl Louw, Michele Tameris, Nishanta Singh, Ameena Goga, Keertan Dheda, Coert Grobbelaar, Natasha Joseph, Johan J. Lombaard, Rosie Mngqibisa, As’ad Ebrahim Bhorat, Gabriella Benadé, Natasha Lalloo, Anna Pitsi, Pieter-Louis Vollgraaff, Angelique Luabeya, Aliasgar Esmail, Friedrich G. Petrick, Aylin Oommen Jose, Sharne Foulkes, Khatija Ahmed, Asha Thombrayil, Dishiki Kalonji, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Alex Marcheschi, Joyce S. Plested, Susan Neal, Gordon Chau, Iksung Cho, Louis Fries, Greg M. Glenn, Shabir A. Madhi

    Published 2024-12-01
    Get full text
    Article

Search Tools: